Sushmita

Sushmita

Screenshot

THE TRANSFORMATION ISSUE NAVLEEN KAUR GHAI

THE TRANSFORMATION ISSUE NAVLEEN KAUR GHAI Beyond the Before-and-After How a 22-kg weight-loss journey became a story about health, resilience, strength—and finding a new purpose By Jaano & Seekho | Human Interest & Wellness Feature There is a temptation, whenever we see a transformation photograph, to look first at the body. We notice the difference…

Read More
Images (2)

NABARD-NaBFID MoU to Boost Rural Infrastructure Funding, Agri Value Chains

NABARD-NaBFID MoU: Rural Infrastructure Funding to Get a Major Boost Jannoandseekho.in | Agriculture Desk Published: August 28, 2026 NABARD and NaBFID Sign MoU to Strengthen Rural Infrastructure Financing The National Bank for Agriculture and Rural Development (NABARD) and the National Bank for Financing Infrastructure and Development (NaBFID) have signed a Memorandum of Understanding (MoU) aimed…

Read More
Advantech mio 5381 01 750x500

Advantech Puts Intel 18A Core Ultra Processors at the Center of Next-Generation Edge AI

Advantech Puts Intel 18A Core Ultra Processors at the Center of Next-Generation Edge AI By JaanoAndSeekho.in Electronic News Desk International Technology News | August 28, 2026 Advantech expands its edge computing portfolio with Intel Core Ultra Series 3 processors, targeting real-time AI, machine vision and intelligent industrial automation. NEW DELHI/LONDON — Advantech is strengthening its…

Read More
Lisraya bottle 1

FDA Approves Priovant’s Lisraya for Rare Autoimmune Skin and Muscle Disease

FDA Approves Priovant’s Lisraya for Rare Autoimmune Skin and Muscle Disease Roivant-backed therapy becomes the first targeted treatment approved for adults with dermatomyositis By PharmaDesk International | JaanoAndSeekho.in August 28, 2026 The U.S. Food and Drug Administration (FDA) has approved brepocitinib, a dual TYK2/JAK1 inhibitor developed by Roivant-backed Priovant Therapeutics, for adults with dermatomyositis (DM)—a…

Read More
Images

FDA Greenlights Revolution Medicines’ Pancreatic Cancer Gamechanger

FDA Greenlights Revolution Medicines’ Pancreatic Cancer Gamechanger By PharmaDesk International | JaanoAndSeekho.in August 28, 2026 FDA approval marks a major milestone for targeted RAS therapy in metastatic pancreatic cancer The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ RAS inhibitor daraxonrasib for the treatment of patients with metastatic pancreatic cancer, marking a potentially…

Read More
631538985 18056760101689641 7444802466986906068 n

HARITHA The Power of Consistency — Building Strength One Rep at a Time

HARITHA The Power of Consistency — Building Strength One Rep at a Time Fitness | Strength Training | Mindset | Women’s Wellness “Not the fastest. Not the strongest. But the most consistent. And that’s enough.” In a fitness culture often dominated by dramatic transformations, extreme workouts and overnight-success narratives, Haritha represents something far more sustainable:…

Read More